GT Biopharma
GTBP
35 hedge funds and large institutions have $3.05M invested in GT Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 6 closing their positions.
300% more call options, than puts
Call options by funds: $4K | Put options by funds: $1K
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.09% less ownership
Funds ownership: 0.65% → 0.56% (-0.09%)
3% less funds holding
Funds holding: 36 → 35 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
46% less capital invested
Capital invested by funds: $5.63M → $3.05M (-$2.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$349K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$28.4K |
| 3 |
Renaissance Technologies
New York
|
+$17.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.92K |
| 5 |
Millennium Management
New York
|
+$8.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$909K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$213K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11.8K |
| 4 |
Jane Street
New York
|
-$2.52K |
| 5 |
Rockefeller Capital Management
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $559 | -$69 | -3 | -8% |
|
|
TF
27
TimeScale Financial
Danvers,
Massachusetts
| $302 | – | – | – |
|
|
IA
28
IFP Advisors
Tampa,
Florida
| $259 | – | – | – |
|
|
BBPWM
29
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $165 | – | – | – |
|
|
ASN
30
Advisory Services Network
Atlanta,
Georgia
| $83 | – | – | – |
|
31
Bank of America
Charlotte,
North Carolina
| $18 | -$23 | -1 | -50% |
|
32
Commonwealth Equity Services
Waltham,
Massachusetts
| $5 | +$7.72K | +337 | New |
|
|
GWSA
33
Global Wealth Strategies & Associates
Denver,
Colorado
| $1 | – | – | – |
|
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$11.8K | -438 | Closed |
|
|
35
Rockefeller Capital Management
New York
| – | -$1K | -57 | Closed |
|
|
CS
36
Credit Suisse
Zurich,
Switzerland
| – | -$157 | -6 | Closed |
|
37
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$136 | -5 | Closed |
|
|
FRA
38
Front Row Advisors
Tiburon,
California
| – | +$46 | +2 | New |
|
GTBP Hedge Fund Activity: Q1 2023 in Review
35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2023, worth a combined $3.05M — down 46% from $5.63M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GTBP and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 7 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $349K. The largest seller was Armistice Capital, cutting an estimated $909K.
- 35 institutional investors held GT Biopharma (GTBP) as of Q1 2023, down from 36 in Q4 2022.
- Funds reported $3.05M of GT Biopharma stock for Q1 2023, down 46% quarter-over-quarter.
- 5 funds opened new GT Biopharma positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest GT Biopharma buyer in Q1 2023 was Bank of Montreal, an estimated $349K added.
- The largest GT Biopharma seller in Q1 2023 was Armistice Capital, an estimated $909K sold.
Based on aggregated 13F filings for Q1 2023.